Nausea, vomiting, diarrhea, and constipation are common during dose escalation
To determine your specific coverage, we recommend contacting your insurance provider directly
The long-term weight-loss agents approved by the FDA of the United States are orlistat, lorcaserin, naltrexone-bupropion, topiramate phenylacetate, LIR, SMG etc
Compared to other weight loss drugs, using GLP-1 agonists increases the risk of pancreatitis (inflammation of the pancreas) by 9 times, bowel obstruction (blockage of the small or large intestines) by 4.5 times, and gastroparesis (a condition that slows or stops the movement of food from the stomach to the small intestine) by 3.6 times
We would like to express their sincere gratitude to the relevant funding committees for the financial support